Stock Analysis on Net

AbbVie Inc. (NYSE:ABBV)

Analysis of Profitability Ratios 
Quarterly Data

Microsoft Excel

Profitability Ratios (Summary)

AbbVie Inc., profitability ratios (quarterly data)

Microsoft Excel
Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Return on Sales
Gross profit margin 70.48% 69.53% 68.96% 67.72% 65.62% 64.82% 66.41% 68.74% 73.56% 77.43% 77.64% 77.32% 77.41% 77.07% 76.44% 75.22% 74.93% 75.18% 75.05%
Operating profit margin 30.33% 32.68% 31.89% 30.09% 28.95% 23.63% 24.81% 28.45% 30.17% 39.86% 39.03% 20.04% 21.85% 19.88% 19.49% 32.99% 32.84% 34.03% 33.99%
Net profit margin 22.04% 22.00% 20.54% 13.66% 12.40% 10.28% 10.08% 18.16% 19.20% 24.77% 23.69% 9.90% 12.62% 16.42% 17.36% 23.50% 20.84% 21.55% 18.82%
Return on Investment
Return on equity (ROE) 86.24% 76.64% 74.91% 55.60% 53.01% 37.63% 35.30% 48.34% 47.30% 179.59% 104.16%
Return on assets (ROA) 8.83% 8.71% 7.88% 5.06% 4.50% 3.43% 3.07% 4.93% 4.65% 9.25% 8.84% 5.48% 7.21% 9.44% 9.58% 11.43% 10.46% 9.20% 7.50%

Based on: 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

Profitability ratio Description The company
Gross profit margin Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. AbbVie Inc. gross profit margin ratio improved from Q4 2021 to Q1 2022 and from Q1 2022 to Q2 2022.
Operating profit margin A profitability ratio calculated as operating income divided by revenue. AbbVie Inc. operating profit margin ratio improved from Q4 2021 to Q1 2022 but then deteriorated significantly from Q1 2022 to Q2 2022.
Net profit margin An indicator of profitability, calculated as net income divided by revenue. AbbVie Inc. net profit margin ratio improved from Q4 2021 to Q1 2022 and from Q1 2022 to Q2 2022.

Profitability ratio Description The company
ROE A profitability ratio calculated as net income divided by shareholders’ equity. AbbVie Inc. ROE improved from Q4 2021 to Q1 2022 and from Q1 2022 to Q2 2022.
ROA A profitability ratio calculated as net income divided by total assets. AbbVie Inc. ROA improved from Q4 2021 to Q1 2022 and from Q1 2022 to Q2 2022.

Gross Profit Margin

AbbVie Inc., gross profit margin calculation (quarterly data)

Microsoft Excel
Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Selected Financial Data (US$ in millions)
Gross margin 10,413  9,486  10,566  9,952  9,436  8,797  9,174  7,852  6,714  6,677  6,698  6,559  6,436  6,134  6,283  6,401  6,344  6,007  5,459  5,379  5,416  4,922 
Net revenues 14,583  13,538  14,886  14,342  13,959  13,010  13,858  12,902  10,425  8,619  8,704  8,479  8,255  7,828  8,305  8,236  8,278  7,934  7,739  6,995  6,944  6,538 
Profitability Ratio
Gross profit margin1 70.48% 69.53% 68.96% 67.72% 65.62% 64.82% 66.41% 68.74% 73.56% 77.43% 77.64% 77.32% 77.41% 77.07% 76.44% 75.22% 74.93% 75.18% 75.05%
Benchmarks
Gross Profit Margin, Competitors2
Amgen Inc. 74.00% 73.30% 73.44% 74.00% 73.97% 74.37% 74.59% 75.55% 77.15% 78.90% 80.38% 81.19% 81.23% 81.26% 81.80% 81.61% 81.78% 81.69% 81.33%
Eli Lilly & Co. 75.98% 74.40% 74.18% 74.85% 74.27% 75.88% 77.66% 78.26% 78.67% 79.22% 78.85% 77.78% 76.67% 74.96% 73.81% 73.39% 72.92% 72.95% 73.46%
Johnson & Johnson 67.86% 67.97% 68.16% 67.51% 67.00% 66.24% 65.58% 65.68% 65.66% 66.15% 66.42% 66.49% 66.67% 66.80% 66.79% 66.36% 65.69% 66.22% 66.84%
Merck & Co. Inc. 70.41% 70.72% 72.02% 67.95% 67.48% 66.99% 67.74% 71.23% 70.06% 70.11% 69.87% 70.13% 69.89% 68.94% 68.06% 67.35% 67.81% 68.22% 68.16%
Moderna Inc. 81.66% 84.26% 85.19% 84.71% 84.49% 89.60% 96.03%
Pfizer Inc. 62.18% 60.35% 62.08% 65.25% 70.96% 76.46% 79.26% 80.47% 80.19% 80.03% 80.25% 79.85% 79.91% 79.36% 79.03% 78.58% 78.24% 78.48% 78.61%
Regeneron Pharmaceuticals Inc. 84.97% 84.65% 84.83% 86.65% 86.85% 86.84% 86.82% 87.98% 88.21% 89.72% 90.05% 91.14% 92.27% 92.79% 93.53% 93.36% 93.28% 92.95% 93.24%
Thermo Fisher Scientific Inc. 46.63% 48.37% 50.08% 51.05% 51.29% 51.47% 49.67% 47.31% 45.39% 44.30% 44.35% 44.48% 44.51% 44.60% 44.57% 44.36% 44.55% 44.68% 45.15%

Based on: 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

1 Q2 2022 Calculation
Gross profit margin = 100 × (Gross marginQ2 2022 + Gross marginQ1 2022 + Gross marginQ4 2021 + Gross marginQ3 2021) ÷ (Net revenuesQ2 2022 + Net revenuesQ1 2022 + Net revenuesQ4 2021 + Net revenuesQ3 2021)
= 100 × (10,413 + 9,486 + 10,566 + 9,952) ÷ (14,583 + 13,538 + 14,886 + 14,342) = 70.48%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Gross profit margin Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. AbbVie Inc. gross profit margin ratio improved from Q4 2021 to Q1 2022 and from Q1 2022 to Q2 2022.

Operating Profit Margin

AbbVie Inc., operating profit margin calculation (quarterly data)

Microsoft Excel
Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Selected Financial Data (US$ in millions)
Operating earnings 3,295  4,717  5,074  4,306  4,441  4,103  3,753  3,255  752  3,603  3,956  2,617  3,400  3,010  (2,441) 3,159  2,762  2,903  1,794  2,705  2,674  2,419 
Net revenues 14,583  13,538  14,886  14,342  13,959  13,010  13,858  12,902  10,425  8,619  8,704  8,479  8,255  7,828  8,305  8,236  8,278  7,934  7,739  6,995  6,944  6,538 
Profitability Ratio
Operating profit margin1 30.33% 32.68% 31.89% 30.09% 28.95% 23.63% 24.81% 28.45% 30.17% 39.86% 39.03% 20.04% 21.85% 19.88% 19.49% 32.99% 32.84% 34.03% 33.99%
Benchmarks
Operating Profit Margin, Competitors2
Amgen Inc. 38.04% 32.78% 31.44% 30.14% 30.72% 37.23% 37.70% 38.59% 39.76% 41.89% 43.57% 44.83% 44.05% 44.53% 45.55% 45.82% 46.46% 46.07% 45.76%
Eli Lilly & Co. 25.50% 25.94% 22.45% 23.17% 21.81% 22.06% 24.69% 23.55% 24.48% 25.64% 22.29% 20.00% 19.48% 12.50% 15.15% 12.34% 9.11% 14.88% 9.38%
Johnson & Johnson 23.47% 23.76% 24.95% 24.69% 25.23% 24.10% 23.60% 24.30% 24.64% 25.62% 24.15% 24.15% 22.63% 22.69% 24.27% 22.59% 23.05% 23.63% 24.07%
Merck & Co. Inc. 33.04% 28.85% 25.74% 14.07% 10.64% 14.02% 16.47% 26.87% 25.40% 25.49% 24.77% 25.56% 26.73% 24.38% 19.62% 17.84% 12.28% 13.57% 16.28%
Moderna Inc. 70.46% 74.34% 75.22% 69.57% 62.28% 32.79% -381.82%
Pfizer Inc. 30.37% 26.12% 23.91% 24.64% 24.12% 21.20% 19.47% 21.17% 21.17% 24.20% 25.46% 26.30% 27.50% 26.86% 26.10% 26.18% 26.00% 25.86% 25.92%
Regeneron Pharmaceuticals Inc. 48.19% 55.08% 55.67% 55.19% 53.94% 43.37% 42.09% 37.43% 34.64% 30.45% 28.10% 29.55% 29.58% 35.41% 37.77% 37.00% 36.89% 36.54% 35.41%
Thermo Fisher Scientific Inc. 22.51% 23.83% 25.57% 27.04% 28.00% 27.68% 24.19% 20.90% 17.05% 17.86% 17.99% 17.88% 18.00% 15.90% 15.53% 15.03% 14.36% 14.23% 14.19%

Based on: 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

1 Q2 2022 Calculation
Operating profit margin = 100 × (Operating earningsQ2 2022 + Operating earningsQ1 2022 + Operating earningsQ4 2021 + Operating earningsQ3 2021) ÷ (Net revenuesQ2 2022 + Net revenuesQ1 2022 + Net revenuesQ4 2021 + Net revenuesQ3 2021)
= 100 × (3,295 + 4,717 + 5,074 + 4,306) ÷ (14,583 + 13,538 + 14,886 + 14,342) = 30.33%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Operating profit margin A profitability ratio calculated as operating income divided by revenue. AbbVie Inc. operating profit margin ratio improved from Q4 2021 to Q1 2022 but then deteriorated significantly from Q1 2022 to Q2 2022.

Net Profit Margin

AbbVie Inc., net profit margin calculation (quarterly data)

Microsoft Excel
Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Selected Financial Data (US$ in millions)
Net earnings (loss) attributable to AbbVie Inc. 924  4,490  4,044  3,179  766  3,553  36  2,308  (738) 3,010  2,801  1,884  741  2,456  (1,826) 2,747  1,983  2,783  52  1,631  1,915  1,711 
Net revenues 14,583  13,538  14,886  14,342  13,959  13,010  13,858  12,902  10,425  8,619  8,704  8,479  8,255  7,828  8,305  8,236  8,278  7,934  7,739  6,995  6,944  6,538 
Profitability Ratio
Net profit margin1 22.04% 22.00% 20.54% 13.66% 12.40% 10.28% 10.08% 18.16% 19.20% 24.77% 23.69% 9.90% 12.62% 16.42% 17.36% 23.50% 20.84% 21.55% 18.82%
Benchmarks
Net Profit Margin, Competitors2
Amgen Inc. 26.73% 23.42% 24.25% 23.03% 23.80% 29.60% 29.97% 30.91% 31.53% 33.64% 35.32% 36.14% 35.57% 35.93% 37.25% 9.96% 10.72% 10.11% 9.08%
Eli Lilly & Co. 19.58% 20.90% 19.71% 21.52% 22.71% 23.91% 25.24% 24.01% 24.48% 23.97% 37.27% 35.10% 33.76% 26.12% 13.16% 1.85% -0.60% 4.82% -0.89%
Johnson & Johnson 19.21% 20.90% 22.26% 19.55% 19.92% 17.95% 17.82% 21.01% 18.86% 20.75% 18.42% 17.32% 20.08% 17.99% 18.75% 1.89% 1.70% 1.58% 1.70%
Merck & Co. Inc. 29.00% 26.27% 26.79% 15.09% 11.83% 15.09% 14.72% 24.33% 22.20% 21.10% 21.01% 20.26% 21.10% 19.50% 14.71% 8.02% 3.25% 3.88% 5.97%
Moderna Inc. 63.31% 66.94% 69.04% 64.55% 57.01% 30.95% -373.77%
Pfizer Inc. 28.94% 27.01% 27.04% 28.74% 23.86% 24.03% 22.95% 18.59% 31.31% 32.32% 31.45% 30.57% 23.58% 21.31% 20.79% 44.63% 42.35% 41.29% 40.55%
Regeneron Pharmaceuticals Inc. 39.97% 48.06% 50.25% 51.65% 50.11% 43.53% 41.35% 38.28% 37.30% 28.56% 26.91% 28.13% 28.59% 35.12% 36.42% 28.24% 25.65% 23.54% 20.41%
Thermo Fisher Scientific Inc. 17.37% 18.49% 19.70% 21.93% 22.47% 22.08% 19.79% 17.12% 14.12% 14.31% 14.47% 14.24% 14.24% 12.89% 12.06% 10.75% 10.36% 10.24% 10.64%

Based on: 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

1 Q2 2022 Calculation
Net profit margin = 100 × (Net earnings (loss) attributable to AbbVie Inc.Q2 2022 + Net earnings (loss) attributable to AbbVie Inc.Q1 2022 + Net earnings (loss) attributable to AbbVie Inc.Q4 2021 + Net earnings (loss) attributable to AbbVie Inc.Q3 2021) ÷ (Net revenuesQ2 2022 + Net revenuesQ1 2022 + Net revenuesQ4 2021 + Net revenuesQ3 2021)
= 100 × (924 + 4,490 + 4,044 + 3,179) ÷ (14,583 + 13,538 + 14,886 + 14,342) = 22.04%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Net profit margin An indicator of profitability, calculated as net income divided by revenue. AbbVie Inc. net profit margin ratio improved from Q4 2021 to Q1 2022 and from Q1 2022 to Q2 2022.

Return on Equity (ROE)

AbbVie Inc., ROE calculation (quarterly data)

Microsoft Excel
Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Selected Financial Data (US$ in millions)
Net earnings (loss) attributable to AbbVie Inc. 924  4,490  4,044  3,179  766  3,553  36  2,308  (738) 3,010  2,801  1,884  741  2,456  (1,826) 2,747  1,983  2,783  52  1,631  1,915  1,711 
Stockholders’ equity (deficit) 14,653  16,283  15,408  13,550  12,569  13,710  13,076  15,270  14,708  (7,415) (8,172) (8,226) (8,566) (7,826) (8,446) (2,921) (3,375) 3,553  5,097  6,687  6,009  4,998 
Profitability Ratio
ROE1 86.24% 76.64% 74.91% 55.60% 53.01% 37.63% 35.30% 48.34% 47.30% 179.59% 104.16%
Benchmarks
ROE, Competitors2
Amgen Inc. 271.85% 624.78% 87.96% 68.26% 69.67% 75.91% 77.20% 67.09% 68.48% 80.92% 81.07% 73.83% 73.73% 74.55% 67.15% 15.35% 15.86% 14.21% 7.84%
Eli Lilly & Co. 66.61% 65.69% 62.16% 76.99% 94.20% 88.31% 109.79% 115.45% 137.26% 179.72% 319.09% 234.97% 282.08% 252.24% 32.88% 3.44% -1.24% 7.74% -1.76%
Johnson & Johnson 24.05% 26.54% 28.20% 25.44% 25.53% 22.96% 23.25% 26.35% 24.11% 28.01% 25.42% 24.31% 26.87% 24.90% 25.60% 2.39% 2.18% 1.97% 2.16%
Merck & Co. Inc. 38.34% 34.68% 34.17% 20.10% 16.73% 26.08% 27.91% 39.47% 37.91% 38.72% 37.99% 34.70% 33.88% 30.50% 23.30% 10.32% 4.12% 4.69% 6.97%
Moderna Inc. 78.15% 85.73% 86.26% 69.75% 52.13% 15.59% -29.17% -21.66% -16.54% -30.82% -43.75%
Pfizer Inc. 33.61% 30.29% 28.47% 26.28% 18.86% 16.23% 15.21% 12.22% 22.05% 24.21% 25.77% 24.91% 21.24% 19.52% 17.59% 33.40% 32.31% 29.72% 29.88%
Regeneron Pharmaceuticals Inc. 27.49% 39.84% 43.03% 40.53% 41.02% 33.43% 31.86% 31.17% 32.94% 18.79% 19.08% 20.41% 21.21% 25.70% 27.91% 22.85% 22.14% 21.74% 19.51%
Thermo Fisher Scientific Inc. 17.59% 18.56% 18.94% 22.13% 23.32% 22.60% 18.47% 15.33% 12.41% 12.85% 12.45% 12.24% 12.33% 11.46% 10.65% 9.55% 9.05% 8.62% 8.76%

Based on: 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

1 Q2 2022 Calculation
ROE = 100 × (Net earnings (loss) attributable to AbbVie Inc.Q2 2022 + Net earnings (loss) attributable to AbbVie Inc.Q1 2022 + Net earnings (loss) attributable to AbbVie Inc.Q4 2021 + Net earnings (loss) attributable to AbbVie Inc.Q3 2021) ÷ Stockholders’ equity (deficit)
= 100 × (924 + 4,490 + 4,044 + 3,179) ÷ 14,653 = 86.24%

2 Click competitor name to see calculations.

Profitability ratio Description The company
ROE A profitability ratio calculated as net income divided by shareholders’ equity. AbbVie Inc. ROE improved from Q4 2021 to Q1 2022 and from Q1 2022 to Q2 2022.

Return on Assets (ROA)

AbbVie Inc., ROA calculation (quarterly data)

Microsoft Excel
Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Selected Financial Data (US$ in millions)
Net earnings (loss) attributable to AbbVie Inc. 924  4,490  4,044  3,179  766  3,553  36  2,308  (738) 3,010  2,801  1,884  741  2,456  (1,826) 2,747  1,983  2,783  52  1,631  1,915  1,711 
Total assets 143,186  143,211  146,529  148,858  147,972  150,501  150,565  149,621  149,530  91,199  89,115  59,441  57,142  56,769  59,352  66,164  61,641  69,342  70,786  68,840  66,994  65,664 
Profitability Ratio
ROA1 8.83% 8.71% 7.88% 5.06% 4.50% 3.43% 3.07% 4.93% 4.65% 9.25% 8.84% 5.48% 7.21% 9.44% 9.58% 11.43% 10.46% 9.20% 7.50%
Benchmarks
ROA, Competitors2
Amgen Inc. 11.09% 9.67% 9.63% 8.63% 9.61% 11.33% 11.54% 11.37% 11.23% 12.45% 13.13% 13.55% 13.40% 12.62% 12.64% 3.27% 3.49% 3.12% 2.48%
Eli Lilly & Co. 12.09% 13.06% 11.44% 12.39% 12.70% 13.01% 13.28% 12.68% 13.39% 13.46% 21.17% 20.97% 20.28% 16.46% 7.36% 1.01% -0.34% 2.53% -0.45%
Johnson & Johnson 10.33% 11.12% 11.47% 9.98% 10.07% 8.76% 8.41% 9.95% 9.59% 11.07% 9.59% 9.10% 10.53% 9.78% 10.00% 0.99% 0.88% 0.79% 0.83%
Merck & Co. Inc. 15.48% 13.29% 12.35% 7.70% 6.14% 7.73% 7.72% 12.83% 11.56% 11.95% 11.66% 11.18% 11.15% 10.20% 7.53% 3.93% 1.58% 1.84% 2.72%
Moderna Inc. 53.97% 53.02% 49.46% 33.75% 21.64% 4.71% -10.18% -12.85% -13.98% -24.46% -32.34%
Pfizer Inc. 15.01% 13.58% 12.11% 11.10% 7.78% 7.01% 6.23% 4.46% 7.97% 9.47% 9.72% 9.51% 8.10% 7.38% 7.00% 14.19% 13.67% 13.21% 12.40%
Regeneron Pharmaceuticals Inc. 20.90% 30.11% 31.75% 29.55% 28.88% 22.53% 20.47% 19.62% 20.68% 14.46% 14.29% 15.38% 15.71% 18.88% 20.83% 16.64% 15.99% 15.23% 13.67%
Thermo Fisher Scientific Inc. 8.21% 8.20% 8.12% 11.64% 12.70% 12.02% 9.23% 7.62% 6.02% 6.25% 6.33% 6.33% 6.11% 5.71% 5.22% 4.66% 4.32% 3.98% 3.93%

Based on: 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

1 Q2 2022 Calculation
ROA = 100 × (Net earnings (loss) attributable to AbbVie Inc.Q2 2022 + Net earnings (loss) attributable to AbbVie Inc.Q1 2022 + Net earnings (loss) attributable to AbbVie Inc.Q4 2021 + Net earnings (loss) attributable to AbbVie Inc.Q3 2021) ÷ Total assets
= 100 × (924 + 4,490 + 4,044 + 3,179) ÷ 143,186 = 8.83%

2 Click competitor name to see calculations.

Profitability ratio Description The company
ROA A profitability ratio calculated as net income divided by total assets. AbbVie Inc. ROA improved from Q4 2021 to Q1 2022 and from Q1 2022 to Q2 2022.